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Epidermal Growth Factor Receptor Silencing Blunts the Slow Force
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Background-—Myocardial stretch increases force biphasically: the Frank-Starling mechanism followed by the slow force response
(SFR). Based on pharmacological strategies, we proposed that epidermal growth factor (EGF) receptor (EGFR or ErbB1) activation is
crucial for SFR development. Pharmacological inhibitors could block ErbB4, a member of the ErbB family present in the adult heart.
We aimed to speciﬁcally test the role of EGFR activation after stretch, with an interference RNA incorporated into a lentiviral vector
(small hairpin RNA [shRNA]-EGFR).
Methods and Results-—Silencing capability of p-shEGFR was assessed in EGFR-GFP transiently transfected HEK293T cells. Four
weeks after lentivirus injection into the left ventricular wall of Wistar rats, shRNA-EGFR–injected hearts showed 60% reduction of
EGFR protein expression compared with shRNA-SCR–injected hearts. ErbB2 and ErbB4 expression did not change. The SFR to
stretch evaluated in isolated papillary muscles was 130% of initial rapid phase in the shRNA-SCR group, while it was blunted in
shRNA-EGFR–expressing muscles. Angiotensin II (Ang II)-dependent Na+/H+ exchanger 1 activation was indirectly evaluated by
intracellular pH measurements in bicarbonate-free medium, demonstrating an increase in shRNA-SCR–injected myocardium, an
effect not observed in the silenced group. Ang II- or EGF-triggered reactive oxygen species production was signiﬁcantly reduced in
shRNA-EGFR–injected hearts compared with that in the shRNA-SCR group. Chronic lentivirus treatment affected neither the
myocardial basal redox state (thiobarbituric acid reactive substances) nor NADPH oxidase activity or expression. Finally, Ang II or
EGF triggered a redox-sensitive pathway, leading to p90RSK activation in shRNA-SCR-injected myocardium, an effect that was
absent in the shRNA-EGFR group.
Conclusions-—Our results provide evidence that speciﬁc EGFR activation after myocardial stretch is a key factor in promoting the
redox-sensitive kinase activation pathway, leading to SFR development. ( J Am Heart Assoc. 2016;5:e004017 doi: 10.1161/
JAHA.116.004017)
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I ncrease in cardiac muscle length after a sudden stretchimmediately leads to a larger contraction. This is classi-
cally attributed to enhanced myoﬁlament responsiveness to
calcium, and allows the heart to increase its output after a
rise in preload or to maintain it despite a greater afterload.
After this initial rise in contractility, myocardial performance
slowly continues to increase, reaching a new steady state
over the next 10 to 15 minutes. Genesis of this slow force
response (SFR) to stretch, widely accepted to be the in vitro
equivalent to the Anrep phenomenon, is still not fully
understood. Cardiac hypertrophy and failure, two of the most
important health problems in Western societies, are triggered
by intracellular signals that occur following myocardial
stretch. The stretch of cardiac muscle activates Angiotensin
II (Ang II) receptor 1a (AT1R), either by autocrine/paracrine
release of endogenous Ang II or directly by mechanical forces
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(see1 for review). Interestingly, the initial steps leading to the
SFR involve similar cellular signals to those implicated in the
development of these diseases.2,3 SFR and cardiac hypertro-
phy are proposed to share the transactivation of the cardiac
epidermal growth factor (EGF) receptor (EGFR) after AT1R
activation as a necessary step for their development (see2 for
review). The EGFR, or ErbB1, belongs to a protein tyrosine
kinase family of four members, all expressed in normal adult
rat hearts except for ErbB3.4 Activation of these receptors is
initiated after ligand binding and is followed by homodimer-
ization or heterodimerization to produce transphosphoryla-
tion.5 ErbB receptor family can be transactivated by a triple
membrane–passing signal mechanism. G protein–coupled
receptors, such as AT1R, mediate activation of membrane-
bound matrix metalloproteases, which cleave membrane-
bound EGF-like ligands, provoking its shedding to the
extracellular space to bind ErbB receptors.5,6 Several models
of cardiac hypertrophy suggest that EGFR transactivation by
AT1R is mediated by heparin-binding EGF (HB-EGF),
7,8 a ligand
that is not exclusive of EGFR, also binding ErbB4.9 Based on a
report using a speciﬁc EGFR inhibitor, AG1478,10 we showed
that EGFR transactivation is required for the development of
SFR following myocardial stretch of cat myocardium.11
Although AG1478 preferentially inhibits EGFR with an IC50
of 3 nmol/L, at the reported doses (1 lmol/L), it could
also inhibit ErbB4 activation.12,13 Therefore, pharmacological
inhibition of EGFR in vivo could provide systemic and
unspeciﬁc inhibition. In the present study, we sought to
speciﬁcally silence EGFR expression in the rat heart to avoid
these inconveniences. A small hairpin RNA (shRNA) directed
to the EGFR was incorporated into a lentiviral vector and
injected into the left ventricular wall of adult Wistar rats. One
month later, the myocardial EGFR-silencing effect on the
proposed stretch-activated signaling pathway2 was analyzed.
Herein, we provide evidence to support that myocardial
stretch activates the EGFR, a critical step for promoting the
redox-sensitive kinase-mediated Na+/H+ exchanger 1 (NHE1)
stimulation that leads to SFR development.
Materials and Methods
All procedures followed during this investigation conform to
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996) and to the guidelines by
the Animal Welfare Committee of La Plata School of Medicine.
Molecular Biology
Plasmids for DNA transfection were prepared with a HiSpeed
Plasmid Maxi Kit (cat. 12662; Qiagen) and alkaline lysis of
Escherichia coli cells method.14 Four different plasmids (three
for the packaging proteins and one for the transgene
expression) members of the lentivirus production system
and mammalian expression plasmid for rat EGFR-GFP have
previously been described (kind gift of Dr Jeffrey E. Segall,
Albert Einstein College of Medicine, New York).15
Cell Culture
Lentiviral constructs and rat EGFR-GFP were expressed by
transient transfection of HEK293T cells using the calcium
phosphate method.16 Cells were grown at 37°C in 5% CO2 in
DMEM, supplemented with 10% (v/v) fetal bovine serum and
1% (v/v) penicillin-streptomycin antibiotic.
Construction and Production of Lentiviral Vectors
A third-generation lentiviral plasmid containing DsRed repor-
ter protein expressing an shRNA sequence against rat EGFR17
was designed (p-shEGFR): 50-cGCATAGGCATTGGTGAATT-30
(positive strand), followed by: 50-TTCAAGAGA-30 (loop), 50-
AATTCACCAATGCCTATGCg-30 (negative strand), and 50-
TTTTTT-30 (terminator). This sequence was ﬂanked by a BamHI
digestion site (50) and a tandem of EcoRI-PacI digestion sites
(30). An EcoRI site was used for screening purposes.
Speciﬁcity of this sequence was conﬁrmed with the Basic
Local Alignment Search Tool (BLAST-NCBI): E value <0.001. A
scrambled shEGFR nucleotide sequence, nonsilencing, was
used as control (50-ATGGCATTGCGATAAGTTG-30, shSCR) and
introduced in the expression vector (p-shSCR). Lentiviral
particles were obtained, co-transfecting HEK293T cells with
the four different plasmids. HEK293T cell media culture was
collected at 24, 48, and 72 hours after transfection and
immediately centrifuged for 10 minutes at 1000 g, virus
containing supernatant was centrifuged for 2.5 hours at
50 000 g. Viral pellets were resuspended in PBS overnight at
4°C, aliquoted, and stored at 80°C. Lentivirus titer was
determined measuring ﬂuorescence of positive HEK293T cells
transduced with serial dilutions of the viral stock in the
presence of 8 lg/mL of polybrene (Sigma). Lentivirus
encoding the nonsilencing sequence was used as control.
Intramyocardial Injection of the Lentivirus
Four-month-old male Wistar rats were anesthetized with
sevoﬂurane (4% for induction and 2–3% for maintenance)
used in a gas mixture with oxygen and delivered through
ventilation by using a positive-pressure respirator (Model 680,
Harvard). After reaching deep anesthesia, a left thoracotomy
was performed via the fourth intercostal space and the lungs
were retracted to expose the heart. Following this, the shRNA-
EGFR or the shRNA-SCR lentivirus (29107 transducing units
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in 200 lL, multiplicity of infection 80) were injected at two
sites in the free wall of the left ventricle, close to the cardiac
apex, using a 30-gauge needle.18,19 Immediately after surgery,
rats were returned to their cages and carried to a recovery
room and subsequently returned to the animal facility until
sacriﬁce (1 month later). Rats had ad libitum access to food
and water.
Echocardiography
Rats were monitored echocardiographically at the end of each
protocol under light anesthesia with sevoﬂurane 4% by
2-dimensional M-mode echocardiography with a 7-MHz trans-
ducer. Measurements were performed according to themethod
proposed by the American Society of Echocardiography.
Isolation of Papillary Muscles, Force, and pHi
Determination
Papillary muscles from the left ventricle were used to assess
the SFR to stretch, as previously described.20 Brieﬂy, the
muscles were mounted in a perfusion chamber placed on the
stage of an inverted microscope (Olympus) and superfused
with a CO2/HCO3
–buffered solution containing (mmol/L)
NaCl 128.3, KCl 4.5, CaCl2 1.35, NaHCO3 20.23, MgSO4 1.05,
and glucose 11.0, and equilibrated with 5% CO2 to 95% O2 (pH
7.40). Possible participation of catecholamines released by
nerve endings was prevented by adrenergic receptor blockade
(1.0 lmol/L prazosin plus 1.0 lmol/L atenolol). The muscles
were paced at 0.2 Hz at a voltage 10% over threshold,
maintained at 30°C, and isometric contractions were
recorded. The cross-sectional area (calculated as 0.75 of
the product of thickness and width) was used to normalize
force records obtained with a silicon strain gauge (model AEM
801, Kronex Technologies Corp). The slack length of each
muscle was determined after mounting, and the muscles were
then progressively stretched to the length at which they
developed maximal twitch force (Lmax). After a few minutes
at Lmax, they were shortened to obtain 95% of the maximal
twitch force (length that approximated 98% of Lmax and
referred to as L98). Then, the muscles were shortened to 92%
of Lmax (L92) and maintained at this length until the
beginning of the stretching protocol to determine the SFR,
which consisted in an abrupt stretch from L92 to L98.
The BCECF epiﬂuorescence technique described elsewhere
was used to measure intracellular pH (pHi).
20 Brieﬂy, after
autoﬂuorescence levels were recorded, the muscles were
incubated for 1 hour in the BCECF-AM–containing solution. At
the end of the loading period, washout of the extracellu-
lar space with dye-free solution was carried out for 30
to 60 minutes before any pHi determination was per-
formed. To limit photobleaching, a neutral-density ﬁlter
(1% transmittance) was placed in the excitation light path. A
manual shutter was used to alternatively select the excitation
ﬁlters (440–495 nm). The experimental protocol used con-
sisted in monitoring NHE1-mediated pHi changes after
applying a unique dose of Ang II (1 nmol/L) in muscles from
shRNA-EGFR– and shRNA-SCR–injected rat hearts. The
experiments were performed in the nominal absence of
bicarbonate (HEPES buffer) to ensure that the only alkalizing
operative pHi regulatory mechanism was the NHE1. HEPES
buffer solution was composed of (mmol/L) NaCl 146.2, KCl
4.5, CaCl2 1.35, MgSO4 1.05, glucose 11.0, and HEPES 10.0,
titrated to pH 7.40 with NaOH and equilibrated with 100% O2.
At the end of each experiment, ﬂuorescence emission was
calibrated by the high KCl/nigericin method described
elsewhere,20 to transform experimental ﬂuorescence ratios
to pHi values.
Measurement of O2˙ Production
Cardiac strips from the left ventricle (195 mm) were
dissected and kept at 4°C until assayed. We used the
lucigenin-enhanced chemiluminescence method to measure
superoxide anion (O2˙) production, as previously described.
21
Brieﬂy, cardiac slices were incubated in assay buffer in the
absence or presence of Ang II (1 nmol/L) and EGF (0.1 lg/
mL), during 30 minutes in a metabolic incubator under 95%
O2 to 5% CO2 at 37°C before measuring O2˙. Chemilumines-
cence in arbitrary units was recorded with a luminometer
(Chameleon; Hidex, Turku, Finland) during 30 seconds each at
4.5-minute intervals for 30 minutes. The lucigenin-containing
assay buffer with tissue slices minus background and the
responses to the drug assayed were reported. O2˙ production
was normalized to milligrams dry weight tissue per minute.
Lipid Peroxidation
Lipid peroxidation was determined by measuring the rate of
thiobarbituric acid reactive substances (TBARS) production,
expressed as nmol/mg tissue. Heart homogenates were
centrifuged at 2000g for 10 minutes. Supernatants (0.5 mL)
were mixed with 1.5 mL trichloroacetic acid (30% w/v), 1 mL
thiobarbituric acid (0.7% w/v), and 0.5 mL water, followed by
boiling for 15 minutes. After cooling, absorbance was deter-
mined spectrophotometrically at 535 nm, using an e value of
1.569105 (mol/L)1 cm1.
NOX Activity
NADPH oxidase (NOX)–dependent superoxide production was
measured in left ventricle homogenates from rats of both
experimental groups, using a previously described lucigenin-
enhanced chemiluminescence method.22 Proteins were
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diluted in modiﬁed HEPES buffer and distributed (100 lg/
well) onto a 96-well microplate. NADPH (100 lmol/L) was
added to wells just before reading. NOX activity measured by
O2˙ production was expressed in cpm/mg of protein over
15 minutes.
Immunodetection
Tissue samples were prepared from freshly isolated heart left
ventricle 1 month after lentiviral injection. The samples were
rinsed with PBS buffer (mmol/L; NaCl 140, KCl 3, Na2HPO4
6.5, KH2PO4 1.5, and pH 7.4) and homogenized in RIPA lysis
buffer (sc-24948), with a protease inhibitor cocktail and PMSF
(sc-24948) and phosphatase inhibitor sodium orthovanadate
(sc-24948). After a centrifugation of 13 000 g for 10 minutes
at 4°C, protein concentration was determined in the super-
natant fraction by the Bradford method. Samples were
prepared by addition of SDS-PAGE sample buffer (20% [v/v]
glycerol, 2% [v/v] 2-mercaptoethanol, 4% [w/v] SDS, 1% [w/v]
bromophenol blue, 150 mmol/L Tris, pH 6.8) and 30 lg of
protein. For the in vitro experiments, transiently transfected
HEK293T cells were rinsed with PBS, and lysates of the whole
tissue culture cells were prepared by addition of SDS-PAGE
sample buffer. Prior to analysis, samples were sheared
through a 26-gauge needle (Becton Dickinson). Samples were
resolved by SDS-PAGE on 10% acrylamide gels. Proteins were
transferred to polyvinylidene diﬂuoride membranes by elec-
trophoresis for 2 hours at 70 V at room temperature in buffer
composed of 20% (v/v) methanol, Tris 25 mmol/L, and
glycine 192 mmol/L. Polyvinylidene diﬂuoride membranes
were then blocked by incubation for 2 hours in T-TBS buffer
(0.1% (v/v) Tween-20, NaCl 137 mmol/L, Tris 20 mmol/L, pH
7.5), containing 10% (w/v) nonfat dry milk, and then
incubated overnight with the corresponding primary antibod-
ies: polyclonal rabbit anti-EGFR, polyclonal rabbit anti-ErbB2,
polyclonal rabbit anti-ErbB4, polyclonal rabbit anti P-p90RSK,
polyclonal rabbit anti-P-ERK1/2, and monoclonal mouse
GAPDH (Santa Cruz Biotechnology). Peroxidase-conjugated
anti-rabbit, anti-mouse, and anti-goat (Santa Cruz Biotechnol-
ogy) was used as secondary antibodies. Bands were visualized
with enhanced chemiluminescence reagent (ECL, Millipore)
and a Chemidoc Station (Bio-Rad) and quantiﬁed using Image
J analysis software.
Confocal Imaging
Left ventricle samples were kept in buffered formalin during
24 hours and then serially cut into 10-lm-thick sections
using a vibratome (Leica VT 1000S). Fluorescence was
detected using a confocal microscope (Olympus FV1000).
Solid-state laser at 559 nm was used for excitation of DsRed
ﬂuorophores. A 94 objective was used for determining viral
distribution in the tissue. For capturing the images, the
intensity of the laser at 559 nm and of its photomultiplier
were kept constant to qualitatively compare the samples.
Epiﬂuorescence Microscopy
DsRed and GFP ﬂuorescence images from HEK293T cells
were obtained with an inverted Olympus 1X71 microscope
equipped with a 100 W halogen lamp. Fluorescence emission
was detected using 575 and 510 nm ﬁlters, respectively.
Statistics
Data are expressed as meanSEM. Student t test or one-way
ANOVA followed by Student-Newman-Keuls test, when appro-
priate, were used to compare data with n>4. Repeated-
measures ANOVA was used to compare post-stretch force
and post-Ang II pHi data against time zero minute in each
experimental group. Two-way ANOVA was used to compare
post-stretch force and post-Ang II pHi curves between groups.
P<0.05 was considered statistically signiﬁcant. Nonparamet-
ric statistic tests, Mann-Whitney or Kruskal-Wallis, were used
to compare data samples with n≤4.
Results
Silencing capability of shEGFR cloned into the lentiviral
transfer plasmid (p-shEGFR) was assessed in vitro in HEK293T.
Cells were transiently transfected with increasing amounts of
pEGFR-GFP and 48 hours later were lysed, electrophoresed,
and immunoblotted with a speciﬁc antibody for EGFR.
Figure 1A shows a strong protein expression of EGFR at its
corresponding expected molecular weight (170 kDa). In
contrast, cells transfected with an empty vector express little
immunoreactive material. As expected, increasing expression
of EGFR-GFP produces an increased green ﬂuorescence
visualized by epiﬂuorescence (Figure 1B). Next, cells were
co-transfected with a constant amount of the pEGFR-GFP
(0.5 lg) and increasing concentrations of p-shEGFR. Since
EGFR-GFP expression is driven by cytomegalovirus promoter
as well as DsRed reporter protein contained in the p-shEGFR,
plasmid transfection with lower amounts of p-shEGFR was
compensated with p-shSCR. Consequently, reduced expres-
sion of EGFR would be the result of EGFR silencing and not less
availability of DNA polymerase. Figure 1C shows an apparent
EGFR expression reduction in cells expressing shEGFR. In
accordance, silencing of GFP expression was evident by the
signiﬁcant reduction in green ﬂuorescence without evident
changes in red ﬂuorescence (Figure 1D).
In order to explore the in vivo capability of the shRNA to
silence the EGFR, silencing (shRNA-EGFR) and control
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(shRNA-SCR) lentivirus were injected into the rat myocar-
dium at two different sites of the left ventricular free wall
near the cardiac apex. Rats were euthanized 1 month later.
Lentivirus spreading was determined by red ﬂuorescence
provided by DsRed protein expressed in heart left ventricle
samples from shRNA-EGFR– and shRNA-SCR–injected ani-
mals, as well as from sham-operated animals (injected with
PBS). A patchy red ﬂuorescence distribution was observed in
both groups of lentivirus-injected hearts, whereas no signal
was detected in the sham-operated group (Figure S1). EGFR
expression measured by immunoblots of left ventricle
homogenates revealed 55% protein reduction in hearts
injected with shRNA-EGFR compared with those injected
with shRNA-SCR (Figure 2A). shEGFR expression did not
affect myocardial expression of other closely related proteins
such as the ErbB family members ErbB2 or ErbB4 (Figure 2B
and 2C, respectively), strongly suggesting its speciﬁcity
against EGFR.
Figure 1. EGFR silencing in HEK293T cells. (A) Lysates of HEK293T cells transiently transfected with 0, 2, and 4 lg of EGFR-GFP plasmid were
analyzed by electrophoresis and immunoblotted. Representative blots and averaged densitometry analysis results normalized to b-actin (each
bar corresponds to n=3). (B) Fluorescent and bright-ﬁeld images of the cell culture transfected with EGFR-GFP plasmid (9100). (C) Lysates of
HEK293T cells were transiently co-transfected with 0.5 lg of EGFR-GFP plasmid and increasing concentrations of shRNA-EGFR coding plasmid
(0, 0.5, 1, 2, and 4 lg, each bar corresponds to n=3). (D) Fluorescence microscope images of the cell cultures transfected with increasing
amounts of p-shEGFR. (Kruskal-Wallis test [A], *P<0.05 vs 0 lg pEGFR-GFP [C], *P<0.05 vs 0 lg p-shEGFR.) EGFR indicates epidermal growth
factor receptor; shRNA, small hairpin RNA.
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We previously observed that SFR is inhibited by the protein
tyrosin kinase inhibitor AG1478,11 at a concentration of
1 lmol/L, which is also capable of inhibiting the ErbB4,12,23
an alternative receptor for the HB-EGF and the endogenous
ligand involved in the process. Therefore, we explored the
functional consequences of chronic EGFR silencing in the
heart. Echocardiographic and morphometric parameters were
evaluated immediately before and after animal sacriﬁce,
respectively. The Table shows that not signiﬁcant differences
between groups were found, suggesting that neither structure
nor basal heart function was affected by chronic EGFR
silencing.
The functional effect of EGFR silencing was analyzed on the
SFR to sudden stretch. Stretching of isolated papillary
muscles from the shRNA-SCR group promoted the
characteristic biphasic mechanical response: an initial abrupt
force increase (expression of the Frank-Starling mechanism)
followed by the SFR (Figure 3A and 3C). However, when the
same protocol was repeated in muscles from shRNA-EGFR–
injected hearts, while the initial rapid phase was preserved,
the SFR was completely canceled (Figure 3B and 3C),
evidencing the key role played by the EGFR in this intrinsic
mechanism, crucial to adapt cardiac output to changes in
hemodynamic conditions.
Cardiac muscle alkalization after stretch in a bicarbonate-
free medium is a consequence of AT1R-mediated NHE1
activation.24 To further characterize the functional effects of
EGFR silencing in the myocardium, we evaluated pHi changes
in response to a low dose (1 nmol/L) of Ang II in both
experimental groups in the nominal absence of bicarbonate.
Figure 2. Left ventricular myocardium ErbB protein expression. Left ventricular tissue from shRNA-EGFR–
or shRNA-SCR–injected hearts were homogenized and lysates analyzed by PAGE and immunoblotting. (A)
Representative immunoblots showing EGFR expression of two different samples from each group (left), as
well as the corresponding overall averaged results obtained from band densitometry analysis (right). (B and
C) Myocardial expression of ErbB2 and ErbB4 members of the EGFR family. Representative immunoblots
(top) and corresponding averaged results (bottom). ErbB expression was normalized to GAPDH expression.
(t test [A and B], Mann-Whitney test [C], *P<0.05 vs shRNA-SCR.) The number of independent experiments
are included in the bars. EGFR indicates epidermal growth factor receptor; shRNA, small hairpin RNA.
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This Ang II dose was selected based on our previous work
showing that it reproduces the signaling pathway triggered by
the stretch, resulting in a similar force increment to the
SFR.25 Basal pHi before addition of Ang II was similar in both
groups of papillary muscles: 7.170.01 (n=7) in the shRNA-
SCR group versus 7.180.01 (n=5) in the shRNA-EGFR group.
A signiﬁcant increase in pHi was detected in muscles from
shRNA-SCR–injected hearts (Figure 4A and 4B). This result
would reﬂect NHE1 activation, since, in the absence of
bicarbonate, it is the only operative alkalinizing mechanism. In
contrast, when Ang II was added to shRNA-EGFR–injected
muscles, pHi moderately decreased instead of increased or
even maintained basal values (Figure 4A and 4B). Although
the available data do not explain the cause of this pHi
decrease in EGFR-silenced myocardium, at ﬁrst glance we can
conclude that these results, together with those presented in
Figure 3, not only clearly indicate that EGFR activation is
crucial for Ang II-triggered NHE1 stimulation, but also
reinforce the notion of the key role played by EGFR
transactivation in SFR development.
Increased NHE1 activity during stretch is dependent of
reactive oxygen species (ROS) formation and activation of
Table. Morphometric and Echocardiographic Parameters
From shRNA-SCR– and shRNA-EGFR–Injected Animals
shRNA-SCR (n=8) shRNA-EGFR (n=11)
Morphometric parameters
BW, g 422.8018.40 381.6718.16
HW, g 1.010.04 0.900.04
LVW, g 0.800.04 0.720.03
TL, mm 42.260.44 41.230.31
HW/BW, 9103 2.400.06 2.360.04
LVW/BW, 9103 1.890.07 1.900.04
HW/TL, 9103 g/mm 23.910.87 21.850.72
LVW/TL, 9103 g/mm 18.830.87 17.580.61
Echocardiographic parameters
LVDD, mm 6.320.15 6.230.13
LVSD, mm 2.460.08 2.420.09
FS, % 60.990.78 61.260.72
LVM, mg 706.4630.61 680.9926.96
LVM/BW, mg/g 1.670.06 1.800.04
LVM/TL, mg/mm 16.690.62 17.400.57
H/R 0.550.01 0.550.01
EGFR indicates epidermal growth factor receptor; FS, fractional shortening; H/R, relative
wall thickness; LVDd indicates left ventricular end-diastolic dimension; LVSd, left
ventricular end-systolic dimension; LVM, left ventricular mass; shRNA, small hairpin RNA.
Body weight (BW), heart weight (HW), left ventricular weight (LVW), and tibia length (TL)
were determined at necropsy. M-mode echocardiographic images were used to quantify
cardiac function.
Figure 3. SFR and EGFR activation. (A) Original force
record obtained in a papillary muscle from an shRNA-SCR–
injected rat heart subjected to a sudden increase in length
from 92% to 98% of Lmax. The biphasic force response to
stretch, initial rapid followed by the SFR, can be observed.
(B) Same as (A) but from a papillary muscle from a shRNA-
EGFR–injected rat heart demonstrating that EGFR silencing
blunt the SFR to stretch. (C) Average SFR data from both
experimental groups expressed as percentage of the initial
rapid phase (Frank-Starling mechanism). The SFR was
calculated as the developed force (peak minus resting
force) at indicated times compared with the developed
force at the beginning of stretch (initial rapid phase=time
zero minute), which was considered as 100%. (Repeated
measures ANOVA, *P<0.05 post-stretch force data vs time
zerominute for each curve; two-way ANOVA, #P<0.05 post-
stretch force curves comparison: shRNA-SCR vs shRNA-
EGFR.) EGFR indicates epidermal growth factor receptor;
SFR, slow force response; shRNA, small hairpin RNA.
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redox-sensitive kinases.21 In the present study, cardiac left
ventricle muscle strips were used to study myocardial O2˙
production in response to Ang II (1 nmol/L) or the speciﬁc
EGFR agonist, EGF stimuli in both experimental groups.
Figure 5A shows that Ang II signiﬁcantly increased O2˙
production in cardiac samples of shRNA-SCR–injected hearts,
whereas this effect was not observed in those in the EGFR-
silenced group. Additionally, when an equipotent concentra-
tion of EGF (0.1 lg/mL) was used to directly stimulate the
EGFR, a signiﬁcant increase in O2˙ production was observed in
the shRNA-SCR group, an effect that was completely abro-
gated in the cardiac strips of the shRNA-EGFR group
(Figure 5A). Since EGFR activation increases ROS production,
the chronic EGFR-silencing effect on basal redox homeostasis
was analyzed. Lipid peroxidation estimated by quantifying
TBARS in shRNA-SCR– or shRNA-EGFR–injected hearts was of
the same magnitude (Figure 5B), indicating that oxidative
stress was similar in both experimental groups. On the other
hand, NOX2, one of the most important sources of O2 in
cardiac tissue that plays an important role in Ang II-induced
cardiac hypertrophy,26 can change its expression in response
to different stimuli.22 In the present study, total NOX activity
(Figure 5C), as well as protein expression level of the NOX2
gp91 membrane subunit (Figure 5D), did not differ signiﬁ-
cantly between groups, indicating that it was not affected by
chronic reduction of the EGFR expression.
We have previously demonstrated that ROS-sensitive
kinases ERK1/2 and p90RSK are responsible for NHE1
activation during myocardial stretch.21 Randomly selected
cardiac left ventricle muscle strips from each heart was
stimulated with Ang II (1 nmol/L) or EGF (0.1 lg/mL) for
15 minutes and frozen immediately after. Immunoblot analysis
of homogenized samples revealed an increase in ERK1/2 and
p90RSK phosphorylation in the shRNA-SCR group, an effect
that was not observed in shRNA-EGFR samples (Figure 6A and
6B). Samples from shRNA-EGFR–injected hearts treated with
Ang II produced a similar amount of ERK1/2 phosphorylation as
the nonstimulated samples. Results from samples treated with
EGF exposed a large mean and standard error, explained by the
ﬁnding that one of the four samples analyzed presented an
exceeded phosphorylation band compared with the rest of the
samples. Duplicate analysis of this sample generated the same
outcome. Overall analysis indicates that neither Ang II nor EGF
stimulation of shRNA-EGFR–injected heart samples induced a
signiﬁcant increase in ERK1/2 or p90RSK phosphorylation.
Total kinases expression measured on immunoblots revealed
no modiﬁed expression of the silenced versus nonsilenced
group (Figure S2).
Taken together, these data support the notion that EGFR
activation after myocardial stretch is an important event of
upstream myocardial ROS production leading to ERK1/2-
p90RSK-NHE1 activation with consequent SFR development.
Discussion
Chronically sustained myocardial stretch in vivo derives in
pathological cardiac hypertrophy. Acute myocardial stretch
ex vivo originates the SFR. Both phenomena share a proposed
initial EGFR transactivation by Ang II, mediated by HB-EGF.2
This agonist has two natural receptors of the membrane
protein tyrosine kinase family in the EGFR and ErbB4. In this
study, we demonstrate that chronic and speciﬁc silencing of
cardiac EGFR with interference RNA is enough to cancel the
SFR, minimizing a potential role of the ErbB4 family member.
Exogenous supply of Ang II to the shEGFR-expressing
Figure 4. pHi changes after Ang II stimulation. Isolated papillary
muscles from shRNA-SCR– or shRNA-EGFR–injected hearts were
loaded with pH-sensitive dye, BCECF, stabilized in bicarbonate-
free solution and then stimulated with a low dose (1 nmol/L) of
Ang II to explore the NHE1 activation. Ang II signiﬁcantly
increased pHi in the shRNA-SCR group, an effect that was not
observed in the EGFR-silenced group, as it can be appreciated in
the original pHi records shown in (A) as well as in the averaged
results depicted in (B) (expressed as DpHi=difference from pre-
Ang II control). (Repeated measures ANOVA, *P<0.05 post-Ang II
pHi data vs time zero minute (pre-Ang II control) for each curve;
two-way ANOVA, #P<0.05 post-Ang II pHi curves comparison:
shRNA-SCR vs shRNA-EGFR). Ang II indicates angiotensin II;
EGFR, epidermal growth factor receptor; NHE1, Na+/H+
exchanger 1; pHi, intracellular pH; shRNA, small hairpin RNA.
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myocardium failed to stimulate active components of the SFR
pathway, such as NHE1 transport, increased ROS production,
and ERK1/2 or p90RSK protein kinases.
We previously observed that treatment with a protein
tyrosine kinase inhibitor (PTKI), AG1478, cancelled the SFR
together with the activation of several proposed components
of the pathway. The AG1478 inhibitor was extensively
described as a speciﬁc EGFR inhibitor with an IC50=3 nmol/
L27 used in cardiac7,11 and noncardiac28 cells or tissues.
AG1478 concentrations used in in vitro experiments are in a
micromolar range, wich is far over EGFR IC50 and even over
ErbB4 IC50 (allegedly, IC50=29.6 nmol/L). In fact, AG1478 in
the micromolar range can also inhibit ErbB4 activation in
tumoral cell lines30 or cardiac cells.12,23
Normal ErbB4 activation by HB-EGF is essential for the adult
heart. Cardiac ErbB2 and ErbB4 has shown a basal phospho-
rylation that is increased on perfusion with HB-EGF.31 In
contrast, in HB-EGF knockout mice, which present several
hearts defects, a very low basal phosphorylation of cardiac
ErbB2 and ErbB4 has been shown.31 Also, in conditional cardiac
ErbB4 knockout mice, dilated cardiomyopathy developed.32 In
addition, pharmacological use of AG1478, during cardiac
studies of transactivation of EGFR, may have also affected
ErbB4 with molecular and physiological consequences.
Figure 5. Myocardial superoxide anion production induced by Ang II or EGF. Cardiac strips from shSCR-
or shEGFR-expressing hearts were stimulated with 1 nmol/L Ang II or 0.1 lg/mL EGF. While both
signiﬁcantly increased superoxide anion production in the scramble group, the effect was canceled in the
EGFR-silenced group (A, results expressed as percentage of nonstimulated control). Importantly, left
ventricle basal oxidative stress (B, estimated by lipid peroxidation through the TBARS method) as well as
basal NOX activity (C, estimated by superoxide production) was not statistically different between groups.
Furthermore, NOX gp91 membrane subunit protein expression level was not affected by the experimental
procedure (D, representative immunoblots and corresponding averaged results from band densitometry
analysis). (ANOVA, *P<0.05 vs control.) The number of independent experiments are included in the bars).
Ang II indicates angiotensin II; EGF, epidermal growth factor; EGFR, EGF receptor; NOX, NADPH oxidase;
shRNA, small hairpin RNA; TBARS, thiobarbituric acid reactive substances.
DOI: 10.1161/JAHA.116.004017 Journal of the American Heart Association 9
EGFR and Slow Force Response Brea et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on N
ovem
ber 25, 2019
We developed an shRNA to silence rat EGFR protein
expression in vitro and speciﬁcally in vivo. By means of
lentivirus, shEGFR was locally expressed in the heart to
produce a 55% reduction of the protein expression without
affecting ErbB2 or ErbB4 protein expression (Figure 2). EGFR
protein expression reduction, although not complete, was
Figure 6. Cardiac ERK1/2 and p90RSK activation by Ang II or EGF stimulation. Cardiac tissue strips were
incubated during 15 minutes either with Ang II (1 nmol/L) or EGF (0.1 lg/mL) and then homogenized,
electrophoresed, and immunoblotted with speciﬁc antibodies to detect ERK1/2 (A) and p90RSK (B)
phosphorylation. In the shRNA-SCR group, Ang II promoted a signiﬁcant p90RSK phosphorylation/
activation and a marginally signiﬁcant increase in ERK1/2 (P=0.057), an effect that was not observed in the
shRNA-EGFR group, as it can be appreciated in the representative blots (top of each panel) as well as in the
corresponding averaged results (bottom of each panel). (Mann-Whitney test [A], t test [B], *P<0.05 vs
nonstimulated control.) The number of independent experiments are included in the bars. Ang II indicates
angiotensin II; EGF, epidermal growth factor; EGFR, EGF receptor; shRNA, small hairpin RNA.
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enough to prevent the SFR to stretch (Figure 3). DsRed
ﬂuorescence distribution observed in both groups of len-
tivirus-injected hearts (Figure S1) revealed a nonuniform
lentivirus spreading from the injection site that left zones of
EGFR expression unaffected, as shown previously.33 Our rat
models with a partial, speciﬁc, and local EGFR reduction in the
heart, did not express cardiac hypertrophy or any other
alteration of heart functional or morphometric parameters
(Table). In contrast, knockout mice with complete EGFR
inhibition in vascular smooth muscle cells and a partial
reduction in cardiomyocytes had a phenotype with mean
blood pressure reduction and cardiac hypertrophy.34 Previ-
ously, we demonstrated that injection of a lentivirus in the
heart produced negligible shRNA silencing in other
organs.18,19 Here, we did not measure EGFR expression away
from the heart, and assume that EGFR expression was not
changed in other tissues.
Increased ROS production is proposed as an early step along
the pathway activated by Ang II during cardiac stretch or
pathological cardiac hypertrophy.2,35,36 Ang II (1 nmol/L)
successively induces an increase in ROS production, activating
ERK1/2 and p90RSK, which phosphorylate NHE1. This path-
way would facilitate sodium entry to the cell and a secondary
intracellular calcium increase. We showed that acute Ang II or
EGF stimulation of left ventricle samples with partial reduction
of EGFR was not able to induce ROS increase (Figure 5). Also,
chronic cardiac expression of shEGFR did not induce any
change in basal redox state or NOX activity. Our results suggest
that EGFR expression is necessary to activate a ROS-mediated
pathway activated by Ang II as described for the SFR.
Previously, systemic administration of EGFR antisense oligonu-
cleotides to rats prevented Ang II-induced ROS-sensitive
ERK1/2 phosphorylation.37 In contrast, EGFR knockout mice
at the vascular smooth muscle cells, with a partial expression in
cardiomyocytes, showed increased basal ROS production and
NOX4 activity.34 This apparent conﬂict likely reﬂects differ-
ences in the silencing time frame and/or tissue localization.
ROS-sensitive ERK kinases are inﬂuenced by ErbB4
signaling. It has been shown that HB-EGF administration to
ErbB4-transfected HEK293 cells can induce ERK1/2 phos-
phorylation, and a similar phosphorylation amount was
apparently obtained by neuregulin 1 (NRG1, a speciﬁc ErbB4
agonist) administration.23 NRG1 in vitro administration to
PC12 cells or to adult cardiomyocytes stimulates ERK1/2
phosphorylation, which is inhibited in a dose-dependent
manner with AG1478. Our results show that the speciﬁc
inhibition of cardiac EGFR is enough to avoid ERK1/2
activation by 1 nmol/L Ang II regardless of a potential
contribution of ErbB4. These are similar results to those
obtained by other authors37 in rats treated with Ang II and
EGFR antisense oligonucleotides as well as in a recently
published paper on H9c2 cells.38
As previously mentioned, myocardial alkalization after
stretch in a nominal bicarbonate-free condition is a manifes-
tation of a stretch-triggered, AT1R-mediated NHE1 activa-
tion.24 In our study, AT1R activation by a low dose of Ang II
increased pHi in papillary muscles from shRNA-SCR–injected
hearts, whereas this effect was not observed in muscles from
the shRNA-EGFR–injected group (Figure 4). We observed an
unexpected decrease in pHi after Ang II addition to the
shRNA-EGFR group instead of remaining close to basal values.
This ﬁnding would be explained if Ang II had affected the
cardiac Slc26a6 anion exchanger, an acidifying pHi regulatory
mechanism that extrudes intracellular OH in exchange for
extracellular Cl, and is negatively regulated by protein kinase
C (PKC).39 On one hand, PKC is responsible for the Ang II-
triggered, NHE1-mediated increase in pHi observed after
myocardial stretch in bicarbonate-free conditions.24 On the
other hand, it has been shown that EGFR activation promotes
PKC activation.40 Therefore, Ang II may trigger EGFR-mediated
PKC activation in shRNA-SCR, promoting PKC-mediated NHE1
activation as well as Slc26a6 anion exchanger inhibition. In
EGFR-silenced myocardium, absence of PKC activation would
avoid NHE1 activation but not Slc26a6 activity, which, by
slowly extruding alkaline equivalents, would favor intracellular
acidiﬁcation. Beyond this unexpected ﬁnding, the observed
result shows that at a low dose of Ang II, EGFR transactivation
is crucial for myocardial alkalization likely due to NHE1
activation. Furthermore, we present conclusive evidence that
speciﬁc inhibition of EGFR in the heart left ventricle allows
cancellation of the SFR to stretch. Taken together, our current
results strongly support the notion that myocardial stretch
activates the EGFR, with this step being critical for promoting
the redox-sensitive kinase-mediated NHE1 stimulation that
leads to SFR development.
Conclusions
EGFR is widely expressed in normal tissues41 where its
activation is part of different physiological signaling pathways.
However, activation of this receptor has also been associated
with pathological conditions of the heart and vasculature, as
well as with the development of diabetes and cancer.42,43
Systemic administration of PTKIs to prevent activation of
cardiac EGFR38 can easily extend its action to other organs44
or even to other proteins such as ErbB4.45 Furthermore, it has
been reported that clinical use of PTKIs during cancer
treatment leads to cardiac toxicity.43 Hence, local and
speciﬁc EGFR inhibition with interference RNA may provide
clear advantages as a potential therapeutic tool in cardiology
clinical practice. In the present work, we show that speciﬁc
inhibition of EGFR in the heart left ventricle allows cancella-
tion of SFR to stretch. Since SFR and pathological cardiac
hypertrophy are described to share a similar sequence of
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molecule activation, local and speciﬁc EGFR inhibition could
be considered as an alternative potential therapy for such
cardiac disease.
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Figure S1 
Figure S1. Myocardial distribution of the lentivirus. Representative confocal images (4X) 
of myocardial slices from hearts injected with shRNA-EGFR or shRNA-SCR lentiviral 
vectors, as well as from a sham-operated rat. Characteristic patchy distribution of red 
fluorescence due to DsRed protein can be observed. The second column presents confocal 
captures from the same slices using different interference contrast (DIC). The third column 
represents merging images obtained from the previous ones (bar = 200 m).  
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Figure S2 
Figure S2. Left ventricular ERK1/2 and p90RSK protein expression. Left ventricular 
stripes expressing shRNA-EGFR or shRNA-SCR were homogenized and lysates analyzed by 
PAGE and immunobloting. Expression of both kinases was unaffected by the experimental 
procedure as it can be appreciated in the representative immunoblots for ERK1/2 (A) and 
p90RSK (B), as well as in the corresponding averaged results (t-test). Expression was 
normalized to GAPDH protein expression.  
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